According to Senator Charles (Chuck) Grassley, the Medicare Modernization Act of 2003 (MMA) has worked out better than expected, but he still keeps a close watch to ensure healthcare dollars are well spent. As chairman of the Senate Finance Committee, Grassley has tremendous clout in Washington. His committee is responsible for tax policy, Social Security, Medicare and Medicaid, which made him a central player in developing and enacting MMA.
According to Senator Charles (Chuck) Grassley, the Medicare Modernization Act of 2003 (MMA) has worked out better than expected, but he still keeps a close watch to ensure healthcare dollars are well spent. As chairman of the Senate Finance Committee, Grassley has tremendous clout in Washington. His committee is responsible for tax policy, Social Security, Medicare and Medicaid, which made him a central player in developing and enacting MMA.
In addition to passing laws, Grassley says it's his job to keep a close watch on how federal agencies carry out Congressional mandates. If a department or government contractor fails to implement approved programs or to meet standards, the senator says he "sinks his teeth in" and doesn't let go until the situation is remedied.
Better than expected
Some prescription drug plans are providing added coverage, particularly options that fill in the "donut hole" in Part D. Providing coverage through the gap would have cost $400 billion, which, Grassley explains, would have doubled the cost of the program. "Now we have plans that don't have donut holes, and we didn't even force it on them," the senator notes.
Grassley is particularly pleased by a significant increase in health plans serving seniors in his home state. "We wanted rural America to have the same competition and choice as urban America in the case of Medicare Advantage. And now there are 44 plans in Iowa, so we don't have to worry about having choice for our people."
No penalties
Implementing the MMA has not been all smiles. Grassley is furious about what he calls a "partisan assault unleashed by Democratic leaders" to convince beneficiaries that it was too difficult to sign up for Part D and not worth the effort. Millions of Americans who enrolled in prescription drug plans (PDPs) and Medicare Advantage drug plans (MA-PDs), however, are benefiting from needed drug coverage, despite the campaign to "sink Medicare Rx," he says.
Grassley also wants to remedy inequities that he feels are hurting small-town pharmacies that provide access to medicines in rural areas. Independent pharmacists have complained that PDPs do not reimburse them in a timely manner and are shifting patients to mail-order pharmacy programs. Grassley is part of a large group of senators urging CMS to ensure policies for local pharmacies. In a letter to CMS Administrator Mark McClellan, MD, in July, the senators pointed to PDP delays in updating listed prices and other actions that make it difficult for pharmacies to participate in Part D.
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Breast Cancer Patients Desire Early, Frequent Financial Screening
November 11th 2024Current financial screening procedures in the United States may need to change, according to recent research done by Laila Gharzai, M.D., LLM, from the Department of Radiation Oncology at Northwestern University.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
The Takeaway From Study of Midlife MS Patients: Don't Stop Disease-Modifying Therapy
Published: November 11th 2024 | Updated: November 11th 2024People with multiple sclerosis (MS) often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop disease-modifying therapy have higher hospitalization rates and more visits to the emergency room.
Read More